Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
2023年12月1日 - 10:30PM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the
“Company”), a specialty pharmaceutical company focused on the
development and commercialization of therapies for the treatment of
neurologic diseases, today announced that Amy Chappell, M.D., FAAN,
will be presenting preclinical in vivo data evaluating BAER-101
using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg
(“GAERS”) model of absence epilepsy at the American Epilepsy
Society (AES) 2023 Annual Meeting in Orlando, FL on December 2,
2023.
The Company's presentation details are as follows:
Title: A Phase 2- Ready
Potentiator of α2/3-Containing GABAA Receptors Potently and Fully
Blocks Seizures in Rats with Genetic Absence EpilepsyPoster
Session and Location: Session 1; West Hall C, Level
2Session Date/Time: Saturday, December 2, 2023,
12:00 p.m. ET Board Number: 1.444
“We are pleased with the progress made with
BAER-101, a molecule with unique pharmacology which has
demonstrated that it can significantly suppress seizures in a
translational animal model of absence epilepsy,” said Alexandra
MacLean, M.D., Chief Executive Officer of Avenue. “The presentation
of preclinical results from this trial showcase BAER-101’s
selectively targeting of GABAA α2 and α3 subtypes more than α1 and
α5, potentially improving anticonvulsant and anxiolytic activity
while minimizing the risk of tolerance and abuse associated with
existing treatments in this drug class. With these compelling
preclinical results in-hand, along with the drug’s proven safety
profile in numerous clinical trials, we are encouraged by
BAER-101’s potential to address the unmet needs of epilepsy
patients.”
BAER-101 underwent preclinical in vivo
evaluation in SynapCell's Genetic Absence Epilepsy Rat from
Strasbourg (“GAERS”) model of absence epilepsy. The GAERS model,
which is a proven, early, informative indicator of efficacy in
anti-seizure drug development with high predictability of response
in humans, mimics behavioral, electrophysiological and
pharmacological features of human absence seizures. In the model,
BAER-101 demonstrated full suppression of seizure activity with a
minimal effective dose of 0.3 mg/kg, PO. The effect was fast in
onset and stable throughout the duration of testing. The
combination of safety and tolerability in hundreds of patients and
the preclinical efficacy data support BAER-101’s continued
development in a Phase 2a trial.
The Company’s poster at AES 2023 will be
available on the Publications section of Avenue’s website at
https://avenuetx.com/publications/.
About BAER-101Avenue is
developing BAER-101 via its subsidiary Baergic Bio for epilepsy
disorders. BAER-101 is a positive allosteric modulator of α2,3
subunit‐containing GABAA receptors with minimal activity at α1 or
α5‐containing receptors, which are believed to mediate many of the
issues impacting the medical use of benzodiazepines such as those
noted with diazepam use (tolerance, dependence, abuse, sedation and
impaired cognition). As a result, BAER-101 may have the potential
to treat epilepsy, anxiety and other disorders in which
benzodiazepines are currently used, while minimizing the
benzodiazepine associated adverse effects. BAER-101 was licensed in
from AstraZeneca with a large safety database in over 700 patients
and an efficacy signal in a subset of patients with anxiety.
About EpilepsyAbsence epilepsy
is a form of epileptic syndrome where patients show generalized
non-convulsive seizures characterized by a brief unresponsiveness
to environmental stimuli and cessation of activity. In human,
typical absence seizures are associated with bilateral, synchronous
and regular spike-and-wave discharges (“SWD”). SynapCell's
world-exclusive model, the GAERS, displays spontaneous SWD and has
become the “state of the art” translational reference model for the
past thirty years. Most of the drugs that have been studied in the
GAERS model show efficacy in focal as well as generalized seizures
in humans.
About Avenue TherapeuticsAvenue
Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical
company focused on the development and commercialization of
therapies for the treatment of neurologic diseases. The Company is
currently developing three assets including AJ201, a first-in-class
asset for spinal and bulbar muscular atrophy, BAER-101, an oral
small molecule selective GABAA α2/3 receptor positive allosteric
modulator for CNS diseases, and IV tramadol, which is in Phase 3
clinical development for the management of acute postoperative pain
in adults in a medically supervised healthcare setting. Avenue is
headquartered in Miami, FL and was founded by Fortress Biotech,
Inc. (Nasdaq: FBIO). For more information, visit
www.avenuetx.com.
Forward-Looking StatementsThis
press release contains predictive or “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements other than statements of current or
historical fact contained in this press release, including
statements that express our intentions, plans, objectives, beliefs,
expectations, strategies, predictions or any other statements
relating to our future activities or other future events or
conditions are forward-looking statements. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “will,” “should,” “would” and
similar expressions are intended to identify forward-looking
statements. These statements are based on current expectations,
estimates and projections made by management about our business,
our industry and other conditions affecting our financial
condition, results of operations or business prospects. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in, or implied by, the
forward-looking statements due to numerous risks and uncertainties.
Factors that could cause such outcomes and results to differ
include, but are not limited to, risks and uncertainties arising
from: expectations for increases or decreases in expenses;
expectations for the clinical and pre-clinical development,
manufacturing, regulatory approval, and commercialization of our
pharmaceutical product candidate or any other products we may
acquire or in-license; our use of clinical research centers and
other contractors; expectations for incurring capital expenditures
to expand our research and development and manufacturing
capabilities; expectations for generating revenue or becoming
profitable on a sustained basis; expectations or ability to enter
into marketing and other partnership agreements; expectations or
ability to enter into product acquisition and in-licensing
transactions; expectations or ability to build our own commercial
infrastructure to manufacture, market and sell our product
candidates; acceptance of our products by doctors, patients or
payors; our ability to compete against other companies and research
institutions; our ability to secure adequate protection for our
intellectual property; our ability to attract and retain key
personnel; availability of reimbursement for our products;
estimates of the sufficiency of our existing cash and cash
equivalents and investments to finance our operating requirements,
including expectations regarding the value and liquidity of our
investments; the volatility of our stock price; expected losses;
expectations for future capital requirements; and those risks
discussed in our filings which we make with the SEC. Any
forward-looking statements speak only as of the date on which they
are made, and we undertake no obligation to publicly update or
revise any forward-looking statements to reflect events or
circumstances that may arise after the date of this press release,
except as required by applicable law. Investors should evaluate any
statements made by us in light of these important factors.
Contact: Jaclyn Jaffe Avenue Therapeutics, Inc.
(781) 652-4500ir@avenuetx.com
Avenue Therapeutics (NASDAQ:ATXI)
過去 株価チャート
から 5 2024 まで 6 2024
Avenue Therapeutics (NASDAQ:ATXI)
過去 株価チャート
から 6 2023 まで 6 2024